The first patient has been treated with an implantable bioelectronic device developed by Galvani Therapeutics, set up by GlaxoSmithKline and Alphabet's Verily Life Sciences in 2016.
Merck KGaA has forged a second partnership in the bioelectronics category in two weeks, teaming up with Innervia to develop neurostimulator devices for treating chronic diseases.
Astellas Pharma is to buy bioelectronic medical devices firm iota Biosciences in a deal worth up to $429m, building on a previous research partnership.
Specialist in innovative therapeutic bioelectronics, Nexeon, is developing advanced implantable medical devices which it hopes will treat hundreds of chronic conditions in the future.
The life sciences industry in the UK is embracing digitalisation, but that is creating a demand for workers with artificial intelligence and data skills that is outstrippi
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas